Ikarian Capital’s Theriva Biologics TOVX Stock Holding History

Ikarian Capital’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28K	Hold	112,076	–	–	﹤0.01%	152
2026 Q1	$21.9K	Hold	112,076	–	–	﹤0.01%	159
2025 Q4	$23.6K	Sell	112,076 -7,955	-7%	-$2.35K	﹤0.01%	171
2025 Q3	$48.6K	Hold	120,031	–	–	﹤0.01%	166
2025 Q2	$52.1K	Hold	120,031	–	–	0.01%	128
2025 Q1	$132K	Buy	+120,031	New	+$168K	0.02%	148

Other funds holding TOVX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

GSC

Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

Ikarian Capital's TOVX Position: Q2 2026 in Review

Ikarian Capital held its Theriva Biologics (TOVX) position steady in Q2 2026 at 112,076 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #152.

Ikarian Capital first reported a position in TOVX in Q1 2025 and has held it in 6 quarters since. The position peaked at $132K in Q1 2025. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

Ikarian Capital held 112,076 shares of Theriva Biologics worth $28K as of Q2 2026.
Ikarian Capital left its Theriva Biologics share count unchanged in Q2 2026.
Theriva Biologics made up ﹤0.01% of Ikarian Capital's portfolio in Q2 2026, its #152 holding.
Ikarian Capital first reported a position in Theriva Biologics in Q1 2025 and has held it in 6 quarters since.
Ikarian Capital's Theriva Biologics position peaked at $132K in Q1 2025.
26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.